PSMC2 is a Novel Prognostic Biomarker and Predicts Immunotherapeutic Responses: From Pancreatic Cancer to Pan-Cancer
Wei Huang(Harbin Medical University), Junli Ding, Zheming Zhang(Wuxi People's Hospital), Zhengtao Qian(Suzhou University of Technology), Jie Mei(Sun Yat-sen University), Rui Hou(Wuxi People's Hospital), Yuxin Shi(Wuxi People's Hospital), Junying Xu(Wuxi People's Hospital)
Cited by 6
Related Papers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
|Journal of Neuroinflammation|2018|268
Voluntary exercise sensitizes cancer immunotherapy via the collagen inhibition-orchestrated inflammatory tumor immune microenvironment
|Cell Reports|2024|70
Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer
|Annals of Oncology|2018|62
In situ pPy-modification of chitosan porous membrane from mussel shell as a cardiac patch to repair myocardial infarction
|Applied Materials Today|2019|62